Pharnext Reports First Half 2022 Financial Results
Following on-schedule completion of patient enrollment, we remain on track to report topline results from our pivotal Phase III PREMIER trial in Q4 2023.
- Following on-schedule completion of patient enrollment, we remain on track to report topline results from our pivotal Phase III PREMIER trial in Q4 2023.
- The first half of 2022 saw Pharnext continue to make significant progress in advancing the development of its lead program, PXT3003, in CMT1A.
- On April 25, 2022, the Board of Directors appointed Joshua Schafer as Chairman of the Board, following his nomination as interim Chairman on March 28, 2022.
- The main financial elements are presented in the table below: These are from financial statements established according to IFRS rules and were approved by the Board of Directors at their meeting held on October 14, 2022.